Lixisenatide Subcutaneous and Recombinate recombinant
Determining the interaction of Lixisenatide Subcutaneous and Recombinate recombinant and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: lixisenatide
Brand name: Adlyxin
Synonyms: Lixisenatide
Generic Name: antihemophilic factor
Brand name: Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Jivi, Obizur
Synonyms: Recombinate (recombinant), Recombinate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lixisenatide Subcutaneous-Recombivax
- Lixisenatide Subcutaneous-Recombivax HB
- Lixisenatide Subcutaneous-Recombivax HB Adult
- Lixisenatide Subcutaneous-Recombivax HB Dialysis Formulation
- Lixisenatide Subcutaneous-Recombivax HB Pediatric/Adolescent
- Lixisenatide Subcutaneous-Recort Plus
- Recombinate recombinant-Lixtraxen Injection
- Recombinate recombinant-LMD
- Recombinate recombinant-LMD Injection
- Recombinate recombinant-LMX 4 Topical application
- Recombinate recombinant-LMX 5
- Recombinate recombinant-LMX 5 Topical application